Old Web
English
Sign In
Acemap
>
authorDetail
>
Lvyu Zhu
Lvyu Zhu
European Automobile Manufacturers Association
Pathology
Medicine
Cell
EGFR T790M
Tyrosine-kinase inhibitor
2
Papers
6
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase I, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma.
2020
Journal of Clinical Oncology
Li Zhang
Hongyun Zhao
Yuxiang Ma
Xin Zheng
Ji Jiang
Yang Zhang
Shaodong Hong
Guizhong Liu
Xiaohong She
Qingjiang Ni
Lvyu Zhu
Yi. Zhu
Fangyong Felix Du
Peter Luo
Show All
Source
Cite
Save
Citations (2)
Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NCSLC).
2019
Journal of Clinical Oncology
Qing Zhou
Lin Wu
Luo Feng
Tongtong An
Ying Cheng
Jianying Zhou
Junling Li
Ji-feng Feng
Li Zhang
Baohui Han
Walson Xu
Lvyu Zhu
Li Xu
Xiao Xu
Feng Roger Luo
Yi-Long Wu
Show All
Source
Cite
Save
Citations (4)
1